HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer - 09/11/19
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 13 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Aim |
A HER2-specific second-generation chimeric antigen receptor (5.137.z) was introduced into NK-92 cells, designated as NK-92/5.137.z cells. To evaluate the function and effectiveness of NK-92/5.137.z cells against gastric cancer cells and further determined whether combination with apatinib can synergize with this NK cell-based practice to better suppress gastric cancer.
Methods |
The expression of HER2 was examined in gastric cancer. The in vitro and in vivo cytotoxic activities of NK-92/5.137.z cells with or without apatinib were evaluated against gastric cancer cell lines.
Results |
HER2 proteins were over-expressed in a considerable proportion of gastric cancer cells. NK-92/5.137.z cells specifically lysed gastric cancer cells expressing HER2 and had higher levels of cytokine production. In vivo, NK-92/5.137.z cells were particularly efficient at eliminating small tumor xenografts, whereas larger solid tumors were not effectively controlled with NK-92/5.137.z cells. Treatment with apatinib increased NK cell infiltration into large tumor xenografts and improved the therapeutic efficacy of NK-92/5.137.z cells.
Conclusion |
NK-92/5.137.z cells could represent a novel treatment option for patients with gastric cancer, either used alone or combined with apatinib.
Le texte complet de cet article est disponible en PDF.Keywords : NK-92, Chimeric antigen receptor, Gastric cancer, Apatinib
Plan
Vol 106 - N° 11
P. 946-958 - novembre 2019 Retour au numéro
Article précédent
- Nouvelles modalités de prescription des autorisations temporaires d’utilisation nominatives (ATUn) : une étape clé dans l’accès à l’innovation
- Stéphane Vignot, Elodie Chapel
- Patients’ perception and attitude to totally implantable venous access for urologic or digestive cancer: A cross-sectional study
- Thomas Vermeulin, Hana Lahbib, Marion Lottin, Caroline Brifault, Josselin Diot, Mélodie Lucas, Emmanuel Huet, Frédéric Di Fiore, Pierre Michel, Pierre Czernichow, Véronique Merle
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?